Effects on Colesevelam HC1 (WelChol®) on Insulin Sensitivity in Subjects With Type 2 Diabetes Mellitus

Completed · Phase 2 · Has a placebo group

Conditions studied: Type 2 Diabetes Mellitus

In brief

This study is designed to test whether WelChol (colesevelam HC1) improves blood sugar control in patients with type 2 diabetes by making their own insulin work more efficiently.

Key facts

Study ID

NCT00361153

Run by

Daiichi Sankyo

People needed

35

Starts

2006-05-01

Expected to finish

2007-03-01

Last updated by the study team

2008-06-25

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects meeting the following criteria at the Screening Visit will be eligible to participate in the trial:
• Have given written informed consent
• Ages 18 to 75 years, inclusive
• Diagnosis of type 2 diabetes mellitus of at least 3 months duration
• HbA1C 7.0- 10.0%, inclusive
• Antidiabetic treatment may include oral agents; all antidiabetic agents must be withdrawn before randomization
• Women may be enrolled if they are not pregnant (negative serum βHCG at the Screening Visit), are not breast-feeding, and do not plan to become pregnant during the trial. In addition, they must either have had a hysterectomy or tubal ligation at least 6 months before signing informed consent, be post-menopausal for 1 year, or practicing an acceptable method of birth control. An acceptable method of birth control may be oral, injectable or implantable hormonal contraceptives, intrauterine device, diaphragm plus spermicide, or female condom plus spermicide. Abstinence, partner's use of condoms, and partner's vasectomy are NOT acceptable methods of contraception
• BMI 25 - 45 kg/M sq, inclusive

You may not qualify if…

• Subjects are excluded from participation in the study if any of the following criteria apply:
• Type 1 diabetes mellitus or history of diabetic ketoacidosis
• Treatment with lipid or blood pressure lowering therapy that has not been stable for three months before randomization
• Treatment with WelChol, cholestyramine or colestipol for hyperlipidemia within the last 3 months
• Treatment with thiazolidinediones
• History of dysphagia, swallowing disorders, or intestinal motility disorder
• Serum triglyceride >500 mg/dL at Visit 1
• Serum LDL-C <60 mg/dL at Visit 1
• Any condition or therapy which, in the opinion of the investigator, poses a risk to the subject or makes participation not in the subject's best interest
• Use of any investigational drug within 30 days before randomization
• Chronic treatment with oral corticosteroids
• History of hyperthyroidism and/or treatment with thyroid hormone/ levothyroxine

Where it is running

• Diabetes and Glandular Research Associates — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.